Virica Biotech and FUJIFILM Biosciences Partner to Enhance AAV Production for Gene Therapy Manufacturing
Key Insights
Virica Biotech (search) and FUJIFILM Biosciences (search) have formed a collaboration under the Canada-Japan Co-Innovation Program to develop enhanced AAV production solutions for gene therapy manufacturing.
The partnership will optimize Virica's Viral Sensitizer (VSE™ (search)) enhancers with FUJIFILM's BalanCD® HEK293 (search) media system to significantly boost AAV yields and process robustness.
The collaboration addresses a critical manufacturing bottleneck in gene therapy, as current AAV production methods struggle to meet growing demand while maintaining commercially viable costs.
Virica Biotech (search) and FUJIFILM Biosciences (search) have announced a strategic collaboration under the Canada-Japan Corporate Co-Innovation Program to address one of gene therapy's most pressing challenges: efficient and cost-effective production of Adeno-Associated Virus (search) (AAV) vectors at scale. The partnership, supported by funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (search) (NRC IRAP), aims to optimize AAV manufacturing processes that currently represent a significant bottleneck for broad patient access to gene therapies.
Addressing Critical Manufacturing Challenges
AAV vectors (search) serve as a cornerstone of in vivo gene delivery for gene therapies, but their production remains both difficult and expensive to scale. As therapeutic pipelines expand to encompass more indications and broader patient populations, the demand for significantly greater amounts of high-quality AAV continues to grow. Simultaneously, the pressure to develop commercially viable therapies places increasing constraints on cost-of-goods, creating a manufacturing challenge that current methods and underlying economics often cannot adequately address.
The collaboration between Virica and FUJIFILM Biosciences (search) specifically targets this challenge by combining high-performance FUJIFILM Biosciences BalanCD media with Virica's Viral Sensitizer (VSE™ (search)) enhancers. This pairing is designed to deliver significant AAV productivity gains while establishing more robust and scalable manufacturing processes.
Technical Approach and Innovation
Under the collaboration framework, Virica will optimize VSE™ (search) formulations and process parameters specifically for AAV production in FUJIFILM Biosciences (search) BalanCD HEK293 media using suspension HEK293 cells (search). The optimization process will leverage Virica's proprietary High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) frameworks, and comprehensive analytical testing capabilities.
FUJIFILM Biosciences (search) will contribute its deep expertise in media and feed supplements, along with proven scale-up capabilities, to the collaborative project. The ultimate goal is to generate VSE™ (search) formulations specifically tailored for the FUJIFILM Biosciences BalanCD HEK293 system, creating an off-the-shelf enhancer-media combination that end users can implement with minimal modifications to existing processes.
Leadership Perspectives
Dr. Jean-Simon Diallo, Scientific Co-founder and Chief Executive Officer of Virica Biotech (search), emphasized the strategic alignment of the partnership: "We see a strong fit between our VSE technology and FUJIFILM Biosciences (search) BalanCD media portfolio. Following the recent launch of our CellVantage™ AAV (search) off-the-shelf enhancer, our goal is to provide an optimized formulation to deliver further AAV productivity gains specifically in the FUJIFILM Biosciences BalanCD HEK293 system."
Yutaka Yamaguchi, Chairman and Chief Executive Officer at FUJIFILM Biosciences (search), highlighted the company's commitment to integrated solutions: "We remain committed to offering integrated solutions that combine high-performance media with enabling technologies. Optimizing Virica's VSE-based enhancers with our FUJIFILM Biosciences BalanCD HEK293 system will help us deliver an easy-to-implement option for improving AAV yields and supporting efficient scale-up for our customers."
Technology Foundation
Virica's VSE™ (search) technology addresses production inefficiencies caused by cellular defenses in manufacturing cells. These purpose-formulated VSE combinations are designed to substantially increase manufacturing yields while reducing cost of goods across a range of viral vector products. The company's approach extends beyond supplying VSEs as off-the-shelf reagents to include fast-turnaround service partnerships that enable rapid optimization of transfection and transduction conditions.
FUJIFILM Biosciences (search) brings over 50 years of experience in cell culture, dating back to 1970, with a comprehensive portfolio supporting life science research, cell and gene therapy, and large-scale production of biotherapeutics and vaccines. The company operates manufacturing facilities that follow cGMP guidelines across the USA, Japan, and the Netherlands, with additional media optimization capabilities in China.
Global Impact Potential
The collaboration addresses a fundamental challenge facing the gene therapy industry as it seeks to expand access to life-changing treatments. By developing solutions that can be readily adopted by both academic and commercial AAV producers worldwide, the partnership has the potential to significantly impact the scalability and economic viability of gene therapy manufacturing. The focus on creating minimal-disruption implementation pathways could accelerate adoption across the industry, ultimately supporting broader patient access to these innovative therapies.